Key facts
- It has raised $6.6M across 4 recorded rounds; the latest was Seed Round ($623K) in Jan 2025.
- NanoPharmaceuticals has filed 4 Form Ds with the SEC since 2014, most recently Feb 2025 ($623K sold to 12 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·Watchlist + deal alerts for NanoPharmaceuticals
Funding rounds
4 roundsAbout NanoPharmaceuticals
Operator of a pharmaceutical company intended to treat cancer and other diseases. The company engages in the discovery and commercialization of new, molecularly targeted drugs for diseases with major unmet needs, enabling clinicians to treat cancer patients efficiently.
- Sector
- Healthcare
- HQ
- Troy, NY, United States
- Founded
- 2013
- Employees
- 2
- Website
- nanopharmaceuticals.com/
- Ownership
- Privately Held (backing)
NanoPharmaceuticals doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in NanoPharmaceuticals shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on NanoPharmaceuticals in its N-PORT filings yet. We sweep new filings monthly.